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Introduction
A major feature of low-insulin states, such as diabetes
mellitus and fasting, is a marked loss of muscle protein
resulting in muscle atrophy (1, 2). In these insulin-defi-
cient states, the amino acids released from muscle protein
are used primarily for hepatic glucose production (2).
Whereas some of the loss of muscle mass in acute dia-
betes is due to decreased protein synthesis, the rapid fall
in tissue weight results primarily from increased protein
degradation (2–5). Streptozotocin administration in rats
leads to destruction of pancreatic beta cells and produces
a useful model of acute insulin deficiency characterized
by high blood glucose levels and ketoacidosis. Protein
degradation in muscles isolated from such rats is also ele-
vated (4, 5). Understanding the enzymatic adaptations
that account for the enhanced muscle protein breakdown
in uncontrolled diabetes and other catabolic diseases may
help in the development of therapeutic regimens or phar-
macological inhibitors of this excessive protein loss.
The bulk of proteolysis in skeletal muscle and most
cultured cells occurs by the ubiquitin-proteasome (Ub-
proteasome) pathway (6, 7), although degradation of
membrane and organellar proteins within lysosomes
also account for 10–20% of the overall protein break-
down (8). In the Ub-proteasome pathway, proteins to be
degraded are first marked by covalent attachment of a
chain of Ub molecules that targets them for destruction
by the 26S proteasome (9). Ub molecules are linked to
the protein substrate by a multienzyme pathway (10).
The enzyme, E1, first activates Ub by forming a high-
energy thiolester linkage between an internal Cys residue
of E1 and the COOH-terminal Gly residue of Ub. Ub is
transferred to a Ub-carrier protein (E2), which then
transfers Ub to a lysine residue of the substrate in a reac-
tion catalyzed by an E3 (Ub-protein ligase). Subsequent-
ly, E2 and E3 link additional Ub molecules onto the first
Ub through isopeptide linkages to form a polyubiquitin
chain. Whereas only a single E1 is present in cells (11), at
least a dozen E2s and probably an even larger number of
E3s exist (12, 13) to provide substrate specificity, because
particular E2/E3 pairs appear to conjugate Ub to specif-
ic cell proteins or classes of proteins. Surprisingly, in rat,
rabbit, and presumably in other mammals, the E2/E3
pair, E214k and E3 a , accounts for most of the Ub conju-
gation activity to endogenous proteins in soluble
extracts of skeletal muscle (6). Ub conjugation by this
pair of enzymes has been termed the “N-end rule path-
way” (14), because the Ub-protein ligase E3 a recognizes
protein substrates that contain basic and large
hydrophobic NH2-terminal amino acids (14, 15), cat-
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Insulin deficiency (e.g., in acute diabetes or fasting) is associated with enhanced protein breakdown in
skeletal muscle leading to muscle wasting. Because recent studies have suggested that this increased
proteolysis is due to activation of the ubiquitin-proteasome (Ub-proteasome) pathway, we investigated
whether diabetes is associated with an increased rate of Ub conjugation to muscle protein. Muscle
extracts from streptozotocin-induced insulin-deficient rats contained greater amounts of Ub-conju-
gated proteins than extracts from control animals and also 40–50% greater rates of conjugation of 125I-
Ub to endogenous muscle proteins. This enhanced Ub-conjugation occurred mainly through the N-end
rule pathway that involves E214k and E3a. A specific substrate of this pathway, a -lactalbumin, was ubiq-
uitinated faster in the diabetic extracts, and a dominant negative form of E214k inhibited this increase
in ubiquitination rates. Both E214k and E3 a were shown to be rate-limiting for Ub conjugation because
adding small amounts of either to extracts stimulated Ub conjugation. Furthermore, mRNA for E214k
and E3a (but not E1) were elevated 2-fold in muscles from diabetic rats, although no significant increase
in E214k and E3 a content could be detected by immunoblot or activity assays. The simplest interpreta-
tion of these results is that small increases in both E214k and E3a in muscles of insulin-deficient animals
together accelerate Ub conjugation and protein degradation by the N-end rule pathway, the same path-
way activated in cancer cachexia, sepsis, and hyperthyroidism.
J. Clin. Invest. 104:1411–1420 (1999).
alyzing their rapid ubiquitination and degradation.
The enhanced muscle protein breakdown in catabolic
conditions seems to occur through activation of the Ub-
proteasome pathway (16, 17). For example, in muscles
removed from acidotic or septic animals and incubated in
vitro, the proteasome inhibitor MG132 lowered protein
degradation to control levels (5, 18–20). Many studies have
shown increases in mRNA for Ub (5, 8, 21–25), E214k (21,
26–29), and certain proteasomal subunits (5, 21, 23, 24,
27–29) in atrophying muscles. However, the increases in
the amounts of these proteins in the muscles have not been
demonstrated or even been measured in most of these
cases. No studies have explored whether the increases in
mRNA for Ub, E214k, or proteasomal subunits can, in fact,
account for the enhanced protein breakdown in atrophy-
ing muscles, or if they are just associated adaptations. Per-
haps the strongest indication that rates of ubiquitination
are generally enhanced in atrophying muscles has been the
finding of increased amounts of Ub conjugates in muscle
from denervated, septic, and tumor-bearing rats (30–33).
Recently, we demonstrated higher rates of Ub conjugation
to muscle proteins in extracts from muscles of tumor-bear-
ing, septic, and hyperthyroid animals (34). Surprisingly,
enhanced Ub conjugation in these muscles again appeared
to occur, in large part, by activation of the N-end rule sys-
tem (34). However, the biochemical adaptations that acti-
vate this pathway have not been investigated.
In rats with acute insulin deficiency, overall protein
degradation in muscle also appears to increase primarily
through activation of the Ub-proteasome pathway, as
suggested by greater sensitivity to proteasome inhibitors
and increased mRNA for Ub and the proteasome (5).
However, rates of Ub conjugation in diabetic muscles
have not been investigated. We demonstrate here that the
activation of proteolysis in insulin-deficient animals is
associated with accelerated Ub conjugation and that
activity of the N-end rule ubiquitination system is
enhanced. To clarify how this system may influence pro-
teolysis, we have examined whether its components, E214k
or E3 a, are rate limiting for Ub conjugation and have
tested whether the expression of these proteins increases
and accounts for the enhanced Ub conjugation.
Methods
Reagents. Ub, anti-Ub antiserum, and human a -lactalbu-
min were purchased from Sigma Chemical Co. (St. Louis,
Missouri, USA), and rabbit reticulocytes were purchased
from Pel-Freez Biologicals (Rogers, Arizona, USA). Chy-
mostatin was obtained from Roche Molecular Biochemi-
cals (Indianapolis, Indiana, USA), and diethylpyrocarbon-
ate (DEPC) was from Fluka Chemie AG (Buchs,
Switzerland). Radioiodination of protein substrates was
performed by the chloramine T method, as described (35).
The dominant negative inhibitor mutants of the E2s were
expressed, purified, and kindly provided by Jackie Pierce,
Margaret Read, and Vincent Chau (Proscript, Inc., Cam-
bridge, Massachusetts, USA). Escherichia coli strains engi-
neered to express rat E214k and human E1 were kindly pro-
vided by S. Wing (McGill University, Montreal, Quebec,
Canada) and Chikara Miyamoto (Nippon Roche K.K.,
Tokyo, Japan), respectively. Polyclonal rabbit antiserum
against E1 was provided by A. Ciechanover (Technion,
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Figure 1
Ub protein conjugates and rates of Ub conjugation are increased in muscles
from diabetic rats. (a) Anti-Ub immunoblot. Muscle extract protein (35 m g
crude extract) from control or diabetic rats was subjected to 15% SDS-PAGE
and probed with a polyclonal anti-Ub antibody at a 1/500 dilution. An
increased amount of high-molecular-weight Ub-immunoreactive material
(Ub conjugates) was present in the muscles from diabetic animals. (b) 125I-
Ub conjugation to soluble muscle proteins. Muscle protein fraction II from
either control (C) or diabetic (DM) rats was used as the source of both Ub-
conjugating enzymes and ubiquitination substrates. Upon addition of
AMPPNP and 125I-Ub, 125I-Ub protein conjugates were formed (lanes 2 and
3). Lanes 4 and 5 are the same as lanes 2 and 3, except for the addition of
2 m M C88S E214k. Lanes 6 and 7 are the same as lanes 2 and 3, except for
the addition of 2 m M C114S E2-C. Lane 1 has 125I-Ub alone. Note that high-
er amounts of Ub-protein conjugates were formed in the extracts from dia-
betic muscles and that the dominant negative E214k, but not the dominant
negative E2-C, inhibited this increase in Ub conjugation. The intensely
radioactive bands at ~ 25 kD in lanes 4–7 are nonreducible 125I-Ub-C88S
E214k and 125I-Ub-C114S E2-C complexes. (c) Ub conjugation to a -lactal-
bumin. Same as in a, except that 125I-Ub was replaced by Ub and 125I-a -lac-
talbumin. Lane 1: 125I-a -lactalbumin alone. Increased 125I-a -lactalbumin-
Ub conjugates were formed in the extracts from diabetic muscles. The
dominant negative E214k, but not the dominant negative E2-C, again inhib-
ited the enhanced Ub conjugation in the diabetic extracts.
Haifa, Israel) and antiserum against E214k was provided by
A. Haas (Medical College of Wisconsin, Milwaukee, Wis-
consin, USA). Muscle extracts were prepared as described
previously (6), with the following modifications. Frag-
ments from multiple (> 4) frozen gastrocnemius muscles
from control or diabetic rats were pooled, pulverized under
liquid N2, and weighed. Four to five volumes of ice-cold
extract buffer (6) was added, and the suspension was
homogenized using 3 pulses (5 seconds) of a Polytron tis-
sue homogenizer (Brinkmann Intruments Inc., Westbury,
New York, USA). Recombinant human E1 and E214k were
purified from overproducing strains of E. coli as described
(6). An enriched preparation of E3a was prepared from a
100,000 g supernatant of rat muscle. The precipitate from
a 40% wt/vol ammonium sulfate [(NH4)2SO4] fractiona-
tion was centrifuged and resuspended in one-tenth the
original extract volume of 20 mM Tris-hydrochloride
(HCl), pH 7.6, 20 mM potassium chloride (KCl), 5 mM
magnesium chloride (MgCl2), 1 mM dithiothreitol (DTT),
and 10% glycerol, and dialyzed overnight against more
than 500 volumes of the same buffer. This fractionation
removes approximately 70% of cell proteins and all E214k.
Diabetic animals. Diabetes was induced in male rats
( ~ 175 g) by a single injection of streptozotocin (125
mg/kg, freshly prepared in 0.1 M citrate buffer, pH 4.0)
in the tail vein. Control rats were injected with buffer
only. Treated and control rats were housed individually
and fed a 23% protein diet; control rats were pair-fed
with streptozotocin-injected rats as described (5, 36).
Rats were studied on the third day after streptozotocin
treatment, after fasting overnight. After anesthesia, arte-
rial blood was collected to measure blood glucose, and
gastrocnemius muscles were excised and immediately
frozen in liquid nitrogen. Muscles were stored at –80°C
until preparation of extracts.
Measurement of Ub conjugation to endogenous soluble mus-
cle proteins. Fraction II (35 m g protein) was incubated with
125I-Ub ( ~ 150,000 cpm, 5–10 m M) in buffer A (20 mM
Tris-HCl, pH 7.6, 20 mM KCl, 5mM MgCl2, 2 mM
AMPPNP, 1 mM DTT, 30 m M MG132, and 10% glycerol).
AMPPNP was used as the energy source for these exper-
iments because it supports activation of Ub by E1 but
not the degradation of ubiquitinated proteins by the
proteasome (37). The reactions (20 m L total volume)
were incubated at 37°C for 60 minutes and terminated
by addition of 6 m l 5 · Laemmli sample buffer. SDS-
PAGE was then performed as described by Laemmli on
13% polyacrylamide gels (38). The gels were dried and
analyzed using a Fuji Phosphorimager.
Measurement of Ub conjugation to human a -lactalbumin.
Fraction II (35 m g protein), 125I-a -lactalbumin (~ 150,000
cpm, ~ 1 m M), and Ub (50 m M) in buffer A (20 m L total
volume) were incubated at 37°C for 60 minutes, termi-
nated by addition of 6 m L 5 · Laemmli sample buffer,
electrophoresed, and analyzed as for the endogenous
ubiquitination reaction above.
E3 a assay. Crude muscle cell extracts (the 100,000 g
supernatant) from control and diabetic rats were deplet-
ed of E2s by precipitation with (NH4)2SO4 (40% wt/vol
final concentration). After centrifugation, the (NH4)2SO4
pellet was resuspended in one-tenth the original extract
volume of 20 mM Tris-HCl, pH 7.6, 1 mM DTT, and 10%
glycerol, and dialyzed overnight against more than 500
volumes of the same buffer. This material was complete-
ly dependent on E214k for Ub conjugation activity (see
Figure 6b). To measure E3a activity, 20 m g of the resus-
pended, dialyzed (NH4)2SO4 precipitate was supple-
mented with E1 (90 nM), 125I- a -lactalbumin ( ~ 100,000
cpm/reaction, 1–5 m M), and E214k (5 m M) in buffer A (20-
m L reaction volume). The reactions were incubated at
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Figure 2
The combination of E214k and E3 a , when added to muscle extracts,
increases the rate of Ub conjugation to an N-end rule substrate. Muscle
extract fraction II (50 m g) was supplemented with recombinant E214k,
E3a [as a 40% wt/vol (NH4)2SO4 precipitate of crude muscle extract], or
a combination of both proteins, and analyzed for Ub conjugation to 125I-
a -lactalbumin after addition of Ub (25 m M) and AMPPNP (2 mM). (a)
Results are graphed as the amount of Ub conjugation measured in the
extract supplemented with added E214k or E3 a divided by the amount of
Ub conjugation measured in the extract without added E214k or E3 a ·
100%. (b) The equivalent amount of fraction II with or without added
E214k and E3 a as was used in a was analyzed by SDS-PAGE and
immunoblot to directly view the quantities of E214k and E3a added to the
reactions. Densitometry analysis of the photographed immunoblots
demonstrated that the reactions supplemented with E214k contained
approximately 3.5 times the amount of E214k present in 50 m g of fraction
II, and the reactions supplemented with E3 a contained approximately
2.3 times the amount of enzyme present in 50 m g of fraction II.
37°C for 60 minutes and terminated by addition of 6 m l
5 · Laemmli sample buffer. SDS-PAGE was then per-
formed as described above.
Production of anti-E3a antibody — overexpression and purifi-
cation of an NH2-terminal E3a fragment. PCR probes were syn-
thesized to introduce an NdeI site, just 5¢ of the AflII site at
–6, and a stop codon and EcoRI site, just 3¢ of the internal
StuI site at +1009 of the mouse UBR1 cDNA (39) (5¢ -AGCT-
GACCATATGCTTAAGATGGCGGACGAAGAG and 5¢ -TAG-
GAATTCTCAAGGCCTGGCAAAATATCTGTC). The probes
were then used to generate the 1.0-kb PCR fragment, which
was cut with NdeI and EcoRI and inserted into a pET28b
vector (Novagen, Madison, Wisconsin, USA). The resulting
plasmid (pSL1) contained a 35-kD NH2-terminal fragment
of the UBR1/E3a gene behind a His6 tag and an IPTG-
inducible promoter. This E3a fragment was purified from
E. coli BL21(DE3) under denaturing conditions using the
His6 affinity matrix Ni-NTA Agarose (Qiagen, Chatsworth,
California, USA) according to the manufacturer’s instruc-
tions. Upon dialysis against PBS, approximately 50% of the
eluted protein remained soluble.
Antibody production. Purified E3 a fragment (150 m g) in
complete Freund’s adjuvant was injected into the
popliteal fossas of 2 rabbits. This initial immunization
was followed by 3 boosts with 100 m g denatured (i.e., not
dialyzed), purified E3a fragment in incomplete Freund’s
adjuvant. George Deegan (Harvard University, Cam-
bridge, Massachusetts, USA) performed antigen injec-
tion and serum collection. IgG was prepared from the
crude rabbit serum using established protocols (40).
Anti-E3 a IgG was affinity purified from the pooled IgG
from both animals according to the procedures of Har-
low (40), using an Affigel-10 matrix (Bio-Rad Laborato-
ries Inc., Hercules, California, USA) onto which the puri-
fied E3a fragment had been bound.
Northern blot analysis. Total RNA was extracted from
muscle, subjected to electrophoresis on agarose-
formaldehyde gels, and transferred to nylon membranes
as described previously (36). Hybridization was per-
formed according to the procedure of Church and
Gilbert (41, 42). Hybridized membranes were analyzed
using a Fuji Phosphorimager. Quantities of specific
mRNA species were normalized for gel-loading differ-
ences by stripping the blots and rehybridizing with an
18S-rRNA probe. The following gel-purified DNA frag-
ments were used as Northern probes: E214k, 0.5-kb XbaI-
BamHI fragment; E3a, 1.0-kb AflII-EcoRI fragment; E1,
0.6-kb NdeI-HindIII fragment; 18S rRNA, 0.75-kb
BamHI-SphI fragment.
Immunoblot analysis. After SDS-PAGE, proteins were
transferred to PVDF membranes (Immobilon; Millipore
Corp., Bedford, Massachusetts, USA) using a semi-dry
transfer apparatus. Membranes were blocked with 5%
nonfat dry milk in PBS and incubated with primary anti-
body (see individual figures) overnight at 4°C. Mem-
branes were then washed twice with PBS plus 0.1%
Tween-100 and once with PBS, then incubated with goat
anti-rabbit IgG (Fc) alkaline phosphatase conjugate
(Promega Corp., Madison, Wisconsin, USA), at a 1:4000
dilution in 5% milk/PBS for at least 3 hours. Membranes
were washed again as above and viewed after treatment
with NBT/BCIP color reagent (Promega) according to
the manufacturer’s instructions. The relative intensities
of bands (i.e., E214k and E3 a ) did not change, even when
immunoblots were intentionally underdeveloped.
Results
As reported previously (5), 3 days after streptozotocin
treatment, serum glucose in rats averaged 288 ± 12
mg/dL compared with 95 ± 9 mg/dL in the control
group (Table 1). The treated animals lost 23% of their ini-
tial body weight during these 3 days, and individual
epitrochlearis muscles underwent marked atrophy, final-
ly weighing, on average, 19% less than epitrochlearis
muscles from control animals (Table 1). To ensure that
changes occurring in the muscles were not due to differ-
ences in food intake between the 2 groups, the control
and streptozotocin-treated animals were pair-fed and
fasted for 12 hours before muscle harvest. When the
epitrochlearis muscles were isolated and incubated in
vitro, those from diabetic rats showed protein degrada-
tion rates 40% greater than the controls (Table 1). This
increase in protein degradation was largely through a
proteasome-dependent pathway because it was marked-
ly inhibited by the proteasome inhibitor, MG132, as well
as ATP depletion (5).
Ub conjugation is increased in muscle extracts from diabetic
rats. To test whether the increased protein degradation in
the muscles of streptozotocin-treated rats was associated
with an increase in Ub conjugation generally, we meas-
ured the content of Ub conjugates in muscles from con-
trol and diabetic animals by subjecting soluble muscle
extracts to SDS-PAGE and immunoblot analysis using an
anti-Ub antibody. The diabetic muscle extract showed
greater amounts of high-molecular-weight Ub-conjugat-
ed proteins than the control muscles (Figure 1a). Larger
amounts of Ub-protein conjugates were also found when
whole muscles from diabetic rats were directly solubilized
in SDS (data not shown). Thus, the increased amount of
Ub conjugates was not the result of extract preparation.
Because the increased protein degradation in the diabet-
ic muscles was sensitive to proteasome inhibitors (5), the
flux of substrates through the proteasome in these atro-
phying muscles must be increased, and this accumula-
tion of Ub conjugates cannot be due simply to a failure of
the conjugates to be degraded. Therefore, the conjuga-
tion of Ub to muscle protein must also be more rapid.
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Table 1
Comparison of normal and diabetic rats
Control Diabetic % of control
Initial body weight (g) 227 ± 3 226 ± 3 99
Final body weight (g) 209 ± 2 174 ± 3A 83
Blood glucose (mg/dL) 95 ± 9 288 ± 12A 303
Epitrochlearis weight (mg) 39.4 ± 1.0 31.8 ± 1.0A 81
Protein degradation in incubated 148 ± 5 208 ± 7A 141
epitrochlearis (nmol tyr/g per hour)
Rats were injected with streptozotocin and sacrificed 3 days later. Control animals
were injected with the buffer, pair-fed, and fasted for the 12 hours preceding mus-
cle harvest. Results are expressed as mean ± SE. Protein degradation was measured
as described previously (5). Protein degradation results are expressed as means ±
SE. Both right and left muscles from each animal were measured independently.
Each group contains 20 measurements. AP < 0.001 for control vs. diabetic groups
by Student’s t test; n = 10 for each group.
This build-up of conjugates in the face of increased pro-
tein breakdown suggests that in the streptozotocin-treat-
ed animals, proteasome function has become the rate-
limiting step in the pathway.
To compare directly rates of Ub conjugation in the mus-
cles of normal and diabetic rats, soluble extracts were pre-
pared and ubiquitination rates measured in vitro as the for-
mation of conjugates between 125I-Ub and endogenous
extract proteins (6). For these studies we used preparations
(fraction II) that contain E1 and many E2s and E3s, includ-
ing those required for the N-end rule pathway, but this frac-
tion lacks Ub (which does not bind to the column) (43–45).
Extracts from the diabetic and control muscles supported
Ub-conjugation to muscle proteins, as measured by the
ATP-dependent incorporation of 125I-Ub into high-molec-
ular-weight protein conjugates (Figure 1b, lane 2). Ub con-
jugates were formed at a faster rate in the extracts from dia-
betic animals than in those from controls (Figure 1b, lanes
3 vs. 2). These findings suggest that the acceleration of Ub
conjugation is a critical adaptation leading to the enhanced
proteolysis in muscles from rats with uncontrolled diabetes.
To test further whether the increase in Ub conjugation
to muscle proteins was due to greater activity of the Ub-
conjugating enzymes and not to some alteration in the
protein substrates in the extracts, we studied Ub conju-
gation to an exogenously added substrate, 125I-human a -
lactalbumin (46). This protein has a basic amino termi-
nus (Lys) and therefore is conjugated to Ub by the N-end
rule pathway. This ubiquitination system, which involves
the enzymes E214k and E3 a (46), selectively conjugates
Ub to proteins with charged or large hydrophobic amino
terminal residues (15), and our recent studies have indi-
cated that this system plays a major role in Ub conjuga-
tion to proteins in skeletal muscle (6). Approximately
twice as much of the 125I-a -lactalbumin was conjugated
to Ub in the extracts from diabetic rats than in the con-
trols (Figure 1c, lanes 3 vs. 2). More rapid ubiquitination
of this exogenous substrate suggests that the N-end rule
pathway is activated in these atrophying muscles.
To test further whether the increase in Ub conjugation
in these muscles from insulin-deficient rats was due to
greater activity of the N-end rule pathway, the effects of
a specific inhibitor of this pathway was studied. A
mutant form of E214k (Cys 88 fi Ser), which forms a sta-
ble ester bond with Ub instead of a thiolester linkage,
can bind Ub but cannot transfer it to E3 or to substrates
(47). This form of E214k acts as a dominant negative
inhibitor of E3 a (47). When added to the Ub-conjuga-
tion assay, it inhibited most of the Ub conjugation to
muscle proteins from both groups (Fig. 1, b and c, lanes
4 and 5) and also decreased or eliminated the difference
between the diabetic and control extracts in the rates of
Ub conjugation to endogenous substrates and to a -lac-
talbumin. By contrast, another dominant negative E2,
E2-C (Cys 114fi Ser), which is not involved in the N-end
rule pathway but inhibits ubiquitination of some cell
cycle proteins (48, 49), had no effect on ubiquitination
rates in extracts from either control or diabetic animals
(Figure 1, b and c, lanes 6 and 7).
Is E214k or E3a rate limiting for Ub conjugation? Because Ub
conjugation by the N-end rule pathway is enhanced in
muscle extracts from the insulin-deficient animals, we
investigated whether either of the enzymes of this pathway
is rate limiting for ubiquitination in these extracts. Pure
E214k, partially purified E3a, or a combination of both was
added to rat muscle fraction II, and rates of Ub conjuga-
tion to 125I-a -lactalbumin were measured (Figure 2). Addi-
tion of either E214k or E3a in amounts sufficient to at least
double cellular levels consistently increased ubiquitination
of 125I-a -lactalbumin, but only by approximately 20% (Fig-
ure 2a). However, increasing the content of E214k and E3a
together stimulated Ub conjugation of 125I-a -lactalbumin
by a larger amount than either alone (about 50%) (Figure
2a), as would be expected if the 2 proteins function togeth-
er. Although increases in either E214k or E3a appear to
enhance Ub conjugation, the quantitative effects of
increasing these factors are difficult to estimate accurate-
ly, because it is unclear to what extent the recombinant
E214k or the partially purified E3a have the same specific
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Figure 3
Muscles from diabetic rats contain higher levels of E214k or E3a , but not
E1 mRNA. (a) Northern blots. Total RNA (15 m g) pooled from 6 muscles
of control or diabetic rats (for the E1 and E3a blots) or from a single con-
trol and diabetic rat (for E214k blot) were electrophoresed, transferred to
nylon membranes, and hybridized with specific E1, E214k, or E3a probes
as described in Methods. (b) Quantification of E214k or E3a transcripts
in muscles from control and diabetic rats. E214k: Mean – SD of mRNA
content for the 1.2-kb E214k transcript in individual muscles from 4 dia-
betic and control rats. E3 a : Mean – SD of mRNA content for the single
6.0-kb E3a transcript in individual muscles from 6 diabetic and control
rats. Quantities of E214k and E3a mRNA were normalized for gel-loading
differences using the 18S rRNA band. The differences in E214k and E3 a
mRNA were statistically significant (P < 0.05) by a 2-tailed Student’s t test.
activity as the endogenous enzymes. Because purification
often results in a partial loss of enzyme activity, the rela-
tively small increases in Ub-conjugation rates observed in
these in vitro experiments probably underestimate the
actual effect of increased synthesis of E3a or E214k in the
cell. In any case, these experiments suggest that even small
increases in E214k or E3a production (e.g., < 50%) in the dia-
betic animals can cause a 40–50% increase in ubiquitina-
tion, as was seen after streptozotocin treatment.
Levels of E214k and E3 a mRNA increase in the diabetic mus-
cles. Because Ub conjugation by the N-end rule pathway
was increased in muscle extracts from diabetic rats, we
measured whether the genes for the components of the
N-end rule pathway are induced in diabetic animals. As
found previously (36), muscles from streptozotocin-
treated rats contained twice as much of the E214k 1.2-kb
transcript as did control muscles (Figure 3), whereas the
abundance of the E214k 1.8-kb transcript was unchanged.
A similar, specific increase in this 1.2-kb E214k transcript
has been seen in muscles undergoing atrophy due to sep-
sis (29), cancer (21), and fasting (26).
We also measured the mRNA levels of E3a, the Ub-pro-
tein ligase that functions together with E214k, and E1, the
Ub-activating enzyme that charges E2 with Ub. The gene
for E3a, also known as UBR1 in yeast, has recently been
cloned from mouse and humans (39). In muscle it is
expressed as a single 6.0-kb transcript. Using the 5 ¢ 1 kb
of the mouse UBR1 gene as a probe for E3 a , we found
that the E3 a mRNA was also elevated about 2-fold in
muscles from diabetic rats (Figure 3). These results
demonstrate coordinate regulation of the 2 specific com-
ponents of the N-end rule pathway. By contrast, mRNA
levels for the Ub-activating enzyme, E1, which is required
for all cellular ubiquitination reactions, was not increased
in the muscles from diabetic rats (Figure 3a).
Preparation and characterization of anti-E3 a antibody. To
determine if increase in the level of E3 a mRNA leads to
an increase in E3a protein in muscles of diabetic rats, we
prepared a polyclonal antibody to a 35-kD NH2-termi-
nal fragment of E3a that was expressed and purified in
E. coli. A polyclonal anti-E3 a IgG was obtained that
reacted with a 200-kD protein in the rat muscle extract,
in good agreement with the predicted molecular weight
for the E3 a gene product.
To establish that this 200-kd immunoreactive band
was indeed E3 a , we immunodepleted E3a from a rabbit
reticulocyte extract (Figure 4).After immunodepletion,
the 200-kD E3 a band was no longer present in the
supernatant (Figure 4a). Furthermore, when the E3 a
activity in the immunodepleted extracts was measured
by assaying Ub conjugation to 125I- a -lactalbumin (Fig-
ure 4b) in the presence of a large excess of recombinant
E1 and E214k, E3 a activity was much lower than in the
untreated extracts or in extracts treated with preimmune
IgG and protein A (Figure 4b, lanes 3 vs. 1 and 2). As
expected, there was no formation of a -lactalbumin Ub
conjugates in reticulocyte extracts in the presence of the
dipeptide LysAla, a competitive inhibitor of E3a, either
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Figure 4
Depletion of E3a from rabbit reticulocyte extract by an anti E3a antiserum. Rabbit reticulocyte fraction II (50 m g) was mixed with buffer, preimmune
IgG (3 m g), or anti-E3 a IgG (3 m g), and rotated at 4°C for 30 hours. Protein A agarose (3 m L) was added to each sample and incubated an addi-
tional 3 hours at 4°C. After sedimentation of the agarose beads, the supernatant and washed beads were separately analyzed. (a) Anti-E3 a
immunoblot of postimmunoprecipitation supernatants. Supernatants of the above reactions were subjected to 8% SDS-PAGE, probed with anti E3a
IgG at a dilution of 1:2000. Treatment of the extract with anti E3a IgG specifically removed a 200-kD immunoreactive band. (b) E3 a activity was
depleted from the postimmunoprecipitation supernatants after treatment with anti-E3a IgG. Supernatants of the above reactions were supplemented
with AMPPNP (2 mM), Ub (25 m M), Ub aldehyde (1 m M), E1 (0.1 m M), E214k (5 m M), and 125I-a -lactalbumin ( ~ 0.75 m M). In the presence of LysAla
(2 mM), a competitive inhibitor of E3a , no Ub-conjugation activity is seen (lanes 4–6). In the presence of the isomeric dipeptide, AlaLys (2 mM),
which does not inhibit E3 a , 125I-a -lactalbumin-Ub conjugates were formed after buffer addition (lane 1) or after immunoprecipitation with preim-
mune IgG (lane 2). However, after immunoprecipitation with anti-E3a IgG, most of the E3 a activity was abolished. (c) Pellets after anti-E3 a IgG
immunoprecipitation contained E3 a activity. Washed protein A agarose beads from the above reactions (4-fold increase in amounts) were supple-
mented with AMPPNP (2 mM), Ub (25 m M), E1 (0.1 m M), E214k (10 m M), and 125I-a -lactalbumin ( ~ 0.75 m M). Only the beads that contained anti-
E3a IgG supported formation of 125I-a -lactalbumin-Ub conjugates.
before or after immunodepletion (6, 15) (Figure 4b, lanes
4–6). Thus, Ub conjugation to this substrate is by E3a
rather than some other Ub-conjugating activity. It is also
noteworthy that the immunoprecipitate retained E3 a
activity; i.e., it was capable of catalyzing Ub conjugation
to a -lactalbumin in the presence of added Ub, AMPPNP,
E1, and E214k (Figure 4c).
Content and activity of E1, E214k, and E3a protein in muscle
extracts. The anti-E3 a antiserum, as well as specific anti-
serum to E1 and E214k, were used to compare the levels of
these proteins in muscles from the insulin-deficient and
control rats. No significant differences were detected in
the content of E1, E214k, or E3 a proteins in the extracts
from diabetic muscles and controls (Figure 5a). To ensure
that the immunoblot analysis was performed in a linear
detection range, known amounts of E214k or partially
purified E3a were detected with the same antibodies (Fig-
ure 5b). This standardization indicates that 2-fold
changes in protein level should be easily detectable.
Because no increase in the content of these proteins
was demonstrable in the gastrocnemius from insulin-
deficient rats, we determined if the activity of E1, E214k,
or E3a, nevertheless, might be increased in these extracts
through some posttranslational modification such as
phosphorylation. E1 and E2 activity was assayed by
measuring the formation of E1-Ub and E2-Ub thiolester
adducts. These linkages are labile but can be seen by
SDS-PAGE in the absence of reducing agents (50). The
muscle extracts from diabetic and control rats showed
similar abilities to activate Ub and to form E2 complex-
es; i.e., the patterns and intensities of E1-125I-Ub and E2-
125I-Ub were indistinguishable (Figure 6a, lanes 2 vs. 3)
and, specifically, the E214k-Ub complexes were of similar
intensities (Figure 6a, arrowhead).
In addition, the activity of E3a was analyzed by meas-
uring Ub-conjugation to a -lactalbumin using (NH4)2SO4
precipitates (40%) of muscle extracts. Any difference in the
rate of Ub conjugation to a -lactalbumin in the 2 extracts
are due to E3a, because endogenous E214k had been
removed (Figure 6b, lanes 2 and 3 vs. lanes 4 and 5) and
equivalent, excess amounts of E214k, E1 and ATP were
added. In control experiments the ubiquitination of a -lac-
talbumin by these preparations was completely inhibited
by LysAla, an inhibitor of E3a (6, 15) (data not shown). In
these assays no consistent difference in E3a activity was
seen in the diabetic and control extracts (Figure 6b, lanes
4 vs. 5), in accord with the measurements of E3a protein.
Discussion
The biochemical mechanisms by which skeletal muscles
undergo rapid protein loss in response to endocrine sig-
nals and cytokines have been of intense interest, largely
because of the debilitating effects of muscle wasting that
accompanies numerous severe diseases (e.g., cancer, renal
failure, sepsis). Many recent studies have suggested that
the primary mechanism for this increased muscle-protein
breakdown in diverse catabolic states is activation of the
Ub-proteasome pathway (16). We demonstrate here that
in muscles from acutely diabetic rats, both Ub-protein
conjugates, the critical intermediates in this pathway, and
rates of their formation are increased. These changes can
account for the overall increase in proteolysis observed in
these muscles (5). Recently, we also demonstrated that in
3 other experimentally induced catabolic states where
muscle-protein breakdown is enhanced (i.e., septic rats,
tumor-bearing rats, and rats treated with high doses of T3
or T4), there was also an increase in Ub conjugation in
muscle extracts (34). In all these cases, this response
occurs in large part through activation of the N-end rule
pathway. This conclusion was based on our findings that
a dominant inhibitor of E3 a (C88S E214k) reduced the
rate of Ub conjugation in the extract of diabetic muscle
to below control levels and that mRNA for this E3
enzyme (E3a ) and its protein cofactor, E214k, were elevat-
ed. Thus, activation of Ub conjugation appears to be a
common adaptation in the development of muscle atro-
phy due to diverse causes. These findings strongly sup-
port the proposal (16, 17, 34) that there is a final, com-
mon cellular mechanism responsible for activating
muscle protein degradation triggered by diverse physio-
logical or pathological factors.
The physiological importance of the N-end rule path-
way has long remained elusive because E3 a recognizes
selectively protein substrates with large, bulky, or
charged NH2-terminal residues, and more than 80% of
intracellular proteins are either N- a -acetylated or begin
with methionine (51). Deletion of the E3 a homologue
in yeast, UBR1, had no clear physiological consequences
(52), and no physiological substrates with these abnor-
mal amino termini have been identified in yeast or mam-
mals. On the other hand, our recent experiments have
demonstrated a major role for E214k and E3 a in overall
Ub conjugation and protein degradation in muscle
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Figure 5
Protein content of E1, E214k, and E3a are similar in extracts from diabet-
ic and control rats. (a) Immunoblots from control and diabetic muscle
extracts. Muscle protein (50 m g of a crude extract for the anti-E214k blot,
and 50 m g muscle extract fraction II for the anti-E1 and anti-E3a blots)
from control or diabetic rats was subjected to SDS-PAGE (9% for the anti-
E1 blot, 15% for the E214k blot, and 8% for anti-E3 a blot) and probed
with the appropriate polyclonal antibody. (b) Immunoblots of known
quantities of E214k and E3 a . Increasing quantities of E214k and E3 a were
subjected to immunoblot analysis as in a above.
extracts from normal rats, but not in cultured HeLa cells
(6). Its special role in skeletal muscle may be related to a
particular role in regulating overall proteolysis in mus-
cle as a potential source of amino acids.
The finding that E214k and E3a are important in the
enhanced protein degradation observed in these diverse
forms of muscle atrophy raises the fundamental question
of how a large fraction of muscle proteins can be sub-
strates for the N-end rule pathway. All muscle proteins are
synthesized with an NH2-terminal methionine and then,
in most cases, have their NH2-termini acetylated; both
should prevent recognition by this system. One possibili-
ty is that in these catabolic states, muscle proteins are
modified to expose novel NH2-terminal residues (e.g., per-
haps by endoproteolytic cleavage or deacylation) that are
recognized by E3a . Alternatively, E3a might recognize
other properties of protein substrates. In fact, yeast UBR1
is able to recognize some substrates (e.g., Ga and CUP9),
that contain an NH2-terminal methionine, presumably
through interaction with internal regions of the proteins
(53, 54). An important goal of future work will be to iden-
tify the polypeptides that undergo ubiquitination by E214k
and E3a in normal and atrophying muscle.
Before these studies, the rate-limiting component in
the Ub-proteasome pathway, either in the degradation
of specific polypeptides or tissue proteins, had not been
systematically studied. We have found that both E214k
and E3 a are rate limiting for Ub conjugation in normal
muscle, as had been suggested by earlier findings (6).
E214k and E3 a not only function together in the N-end
rule pathway but their expression is coordinately regu-
lated because mRNA for both enzymes increased in the
diabetic muscles at a time when other genes (rRNA, E1)
remained constant. Because E1 is required to activate
ubiquitin before all its conjugation reactions, it is unlike-
ly that E1 would be rate limiting for Ub conjugation,
and, in fact, its addition to muscle extract did not aug-
ment protein degradation (6).
Surprisingly, in muscles from these insulin-deficient
rats, despite the 2–3-fold increase in Ub protein conju-
gates, the 40–50% increase in the rate of Ub conjugation
by the N-end rule pathway, and the 2-fold elevations in
mRNA for E214k and E3 a , no consistent differences in
the corresponding levels or activities of these enzymes
could be demonstrated. These results emphasize the
potential danger in extrapolating from measurements of
increases in mRNA levels to enhanced protein expres-
sion, as has often been done in studies of the Ub-protea-
some pathway in atrophying muscle (5, 8, 21–29).
Whereas it is possible that E214k or E3 a protein levels
might rise at a later time during the development of dia-
betes, at the time these experiments were performed (3
days after streptozotocin administration), the adapta-
tions responsible for the major loss of muscle protein in
diabetic animals are functioning because protein degra-
dation in incubated muscles was elevated by approxi-
mately 40%, the animals had already lost more than 20%
of their initial body weight, and Ub conjugation rates
had already increased (36). Another example of an
increase in mRNA without an increase in protein con-
tent is branched chain ketoacid dehydrogenase in the
muscle of acidotic animals (55). Perhaps the high levels
of mRNA for these enzymes may indicate an increased
rate of their synthesis, which may be necessary just to
maintain high levels of the enzymes in atrophying mus-
cles in the face of accelerated protein breakdown.
The simplest explanation for the apparent discordance
between our findings of an increase in the overall rate of
Ub conjugation and both mRNA for E214k and E3 a in
the diabetic extracts and the lack of demonstrable
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Figure 6
E1, E214k, and E3a activity is similar in extracts from diabetic and control
rats. (a) E1/E2 assay. To measure formation of E1-Ub and E2-Ub
adducts, fraction II of muscle extracts (100 m g) from diabetic (lanes 3
and 5) or control (lanes 2 and 4) rats were mixed with AMPPNP (2 mM)
and 125I-Ub ( ~ 2.5 m M) and incubated at room temperature for 10 min-
utes. To distinguish thiolesters from Ub-conjugated proteins, half the
reaction was mixed with sample buffer in the absence (lanes 2 and 3) or
presence (lanes 4 and 5) of DTT (100 mM final concentration) and ana-
lyzed on 15% SDS-PAGE. Lane 1 contains 125I-Ub ( ~ 2.5 m M), E1 (0.66
m M), E214k (0.47 m M), and AMPPNP (2 mM) only. Bands present in lanes
2 and 3 but not lanes 4 and 5 reflect 125I-Ub-E2 thiolester adducts.
Arrowhead marks position of 125I-Ub- E214k. The set of E2s and their
abundance are the same in the extracts from the control and diabetic ani-
mals. (b) E3 a activity in extracts of control and diabetic animals. To
measure E3 a activity, muscle extracts from control and diabetic animals
were depleted of E2s by precipitation with (NH4)2SO4 (40% wt/vol final
concentration). The precipitated material after resuspension and dialy-
sis was supplemented with AMPPNP, E1, 125I- a -lactalbumin, and E214k
(lanes 4 and 5). The appearance of 125I-a -lactalbumin-Ub conjugates was
strictly dependent on addition of E214k, and no difference in rates of con-
jugation was seen in the 2 groups (lanes 4 and 5).
increases in the amount of E214k or E3 a protein may
stem from the lack of sufficient sensitivity in the assays
used to measure these proteins or their activities. Detec-
tion of mRNA is more sensitive and requires less manip-
ulation of the tissue than the enzymatic assays used here.
In fact, immunoblot analyses can easily miss 30% differ-
ences in protein content. In addition, there is evidence in
mammals of an additional isoform of UBR1 of similar
molecular weight (39). If this additional form exists and
is recognized by our antibody, it would be even harder to
demonstrate increases in one form of E3 a if the other
does not change. Finally, a failure to detect small increas-
es in E214k and E3 a seems quite possible in light of the
data in Figure 2, which shows that small increases in
E214k and E3a act in an additive or synergistic manner in
promoting Ub conjugation. Whereas we may have been
unable to detect small increases in E214k or E3 a individ-
ually in muscle extracts from insulin-deficient animals,
when coupled together in vivo, changes in overall Ub-
conjugation rate might become detectable.
If E214k or E3a changes are not responsible for the
enhanced Ub conjugation and protein degradation in dia-
betic rats, then another explanation for these changes must
exist. Ubiquitin isopeptidase activity, which is known to dis-
assemble polyubiquitin chains (56), could, in theory, be
decreased in the muscles from diabetic rats. In fact, such
regulation has been proposed to be involved in memory for-
mation in Aplysia (57). Differences in isopeptidase activity
do not appear to occur in extracts from diabetic rats, how-
ever, because the addition of the isopeptidase inhibitor,
ubiquitin aldehyde (58), increased Ub conjugation rates to
a similar extent in extracts from control or diabetic muscles
(Stewart Lecker, unpublished results). Finally, an unidenti-
fied enzyme or cofactor could be more active or induced by
diabetes to act with E214k and E3a to enhance Ub conjuga-
tion. Proteins that increase the efficiency and processivity
of Ub-conjugation reactions (e.g., Rbx1 and homologues)
have recently been found to enhance Ub conjugation to G1
cyclins (59), and a new factor termed E4 can act with E1, E2,
and the Ub protein ligase to elongate Ub chains on partic-
ular protein substrates (60).
Finally, in the N-end rule pathway, there are enzymes
that can modify certain polypeptides so they can be ubiq-
uitinated by E3a . For example, arginyl tRNA protein trans-
ferase (ATE1) can add arginine to the NH2-termini of
polypeptides that bear Asp or Glu residues (61), and NH2-
terminal amidase (NTA1) can deamidate NH2-terminal
Asn and Gln residues to produce Asp and Glu, respective-
ly (62). If these enzymes were more active or abundant in
extracts from diabetic muscles, then higher rates of Ub
conjugation might be seen. However, we found that a -lac-
talbumin, a protein that does not need further modifica-
tion to be recognized by E3a  (because of its NH2-terminal
lysyl residue) (46) was ubiquitinated at a faster rate in mus-
cle extracts from diabetic rats, indicating that the enzymes
that ubiquitinate a -lactalbumin (i.e., E214k and E3a ) are
the ones changing in the diabetic extracts.
In summary, even with the new experimental tools intro-
duced here, it is difficult to dissect critical adaptations
when the magnitude of the overall changes occurring is
small (20% decrease in muscle weight over 3 days and 40%
change in Ub-conjugation rate) and may be multifactorial,
i.e., involving smaller changes in multiple proteins. Regard-
less, a 20% reduction in muscle mass can be highly debili-
tating and, if progressive, would cause an insurmountable
loss of tissue protein in the organism as a whole.
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